TrialCancer2019

A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.

Weijing Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.